Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed Hodgkin's lymphoma meeting the following criteria:~  * Newly diagnosed disease~ * Stage IA OR stage IIA without bulky disease~ * No lymphocyte-predominant histology~* Staging on this study will be determined by the clinical stage; surgical staging is strongly discouraged, except for the rare situation of equivocal imaging studies below the diaphragm~* Patients may not have received any previous chemotherapy or radiation therapy; patients may not have received systemic corticosteroids within 30 days of enrollment on this protocol; steroids used for treatment of contrast agent allergy required for computed tomography (CT) scans are acceptable~* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^3~* Total bilirubin =\< 1.5 x normal~* Alanine (ALT) =\< 2.5 x normal~* Shortening fraction \>= 27% by echocardiogram OR ejection fraction \>= 50% by multi-gated acquisition (MUGA)~* No pathologic prolongation of QTc interval on 12-lead electrocardiography (ECG)~* Female patients of childbearing potential must have a negative pregnancy test~* Lactating females must agree that they will not breastfeed a child while on this study~* Fertile patients must use effective contraception~* Males and females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method~* All patients and/or their parents or legal guardians must sign a written informed consent~* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim (Type: EXPERIMENTAL): Treatment consists of 3 cycles of Doxorubicin hydrochloride IV (25 mg/m2) days 1 \& 2, Vincristine sulfate IV (1.4 mg/m2 \[max 2.8 mg\]) Days 1 \& 8, Prednisone orally (40 mg/m2) Days 1-7, Cyclophosphamide IV (600 mg/m2) Days 1 \& 2, Filgrastim by mouth or IV (5 micrograms/kg/dose) 24 hours after Cyclophosphamide complete. See detailed description for remainder of therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).